Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational…
[Read More …]
from Back Pain Relief, http://www.xbackpain.com/amgen-ucb-present-romosozumab-phase-2-results-at-endo-2017/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.